A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia

This study has been completed.
Information provided by:
Erimos Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: September 8, 2005
Last updated: August 10, 2006
Last verified: August 2006
The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.

Condition Intervention Phase
Cervical Intraepithelial Neoplasia
Drug: EM-1421
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus

Resource links provided by NLM:

Further study details as provided by Erimos Pharmaceuticals:

Estimated Enrollment: 8
Study Start Date: September 2004
Estimated Study Completion Date: July 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Negative pregnancy test
  • Biopsy confirmed CIN 1, 2, or 3

Exclusion Criteria:

  • Pregnancy or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00154089

United States, Delaware
Planned Parenthood of Delaware
Wilmington, Delaware, United States, 19801
United States, Maryland
University of Maryland, Dept. of Family Medicine
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Erimos Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00154089     History of Changes
Other Study ID Numbers: EM-1421 #201 
Study First Received: September 8, 2005
Last Updated: August 10, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Erimos Pharmaceuticals:
cervical intraepithelial neoplasia

Additional relevant MeSH terms:
Carcinoma in Situ
Cervical Intraepithelial Neoplasia
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on February 04, 2016